| Drug Name | ***0068 |
| Description |
A monoclonal antibody targeting an epitope of the extracellular domain of leukosialin (CD43) is in early clinical investigation for the treatment of leukemia. |
| Target | CD34 |
| Drug Modality | Antibody |
| Indication | Leukemia |
| Product Category | Cancer Immunotherapy |
| Mechanism of Action | Anti-CD43 |
| Status | Phase I |
| Patent | Granted |
We look forward to hearing from you.
Protheragen's business is growing rapidly after founded in New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.
 |
Protheragen Inc. |
 |
Quick Links |